Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Domain Therapeutics, Universite de Montreal, IRICoR and McGill University Sign Agreement

Published: Thursday, December 26, 2013
Last Updated: Thursday, December 26, 2013
Bookmark and Share
New licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.

Domain Therapeutics has announced the signing of a licensing and partnership agreement on GPCR biosensor technology with the Universite de Montreal (UdeM) and its commercialization unit, the Institute for Research in Immunology and Cancer -Commercialization of Research (IRICoR), and McGill University.

The GPCR biosensor technology was developed with the support of a grant from the Quebec Consortium for Drug Discovery (CQDM), whose mission is to fund breakthrough technologies with the financial support of major pharma companies. This project was overseen by a team of researchers from UdeM’s Institute for Research in Immunology and Cancer (IRIC) led by Dr. Michel Bouvier. Dr. Bouvier is internationally renowned for his work on GPCRs.

The agreement gives Domain Therapeutics co-exclusive access, with AstraZeneca, Merck and Pfizer participating via the CQDM, to biosensor technology developed by Dr. Bouvier’s team. This new approach, which makes it possible to discriminate the functional activation of intracellular signalling pathways associated with GPCRs, is considered a prime technology for accelerating the discovery and development of biased ligands for this class of receptors.

In addition, Domain Therapeutics will offer a unique service in profiling drug candidates for the pharma and biotech industries. Domain Therapeutics also leverages a screening platform called DTect-All™, designed to discover innovative drugs that target GPCRs. By combining the two technologies, Domain Therapeutics can discover and optimize more effective non-toxic therapeutic candidates for its internal programs and for collaborative programs with industry partners.

The biosensor technology already covers more than twenty signaling pathways and, under the terms of the agreement, a partnership will also be set up for the joint development of additional biosensors. IRIC researchers and their colleagues from UdeM, McGill University and Universite de Sherbrooke will contribute their research expertise in molecular pharmacology.

“This technology, which is unique in the world, strengthens our capacity to discover the drugs of tomorrow, which will be more effective and safer,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “The scientific quality of Dr. Michel Bouvier’s lab and his international reputation offer our company tremendous expertise in the future use of this technology.”

“The combination of our innovative approaches leading to a joint project that brings together our complementary expertise is extremely good news. Improving the efficacy of existing drugs and developing new drugs require establishing innovative partnerships like this one with Domain Therapeutics,” said Michel Bouvier, principal investigator at IRIC and CEO of IRICoR.

Under the terms of the agreement with the UdeM, Domain Therapeutics will make an upfront payment on signing. The company will also pay an annual access fee for the technology, as well as royalties on income earned from sales of screening services and sales of drugs resulting from its own research and partnership activities. Domain Therapeutics will also provide financial support for the discovery of new biosensors.

“We welcome this highly promising partnership to develop the drugs of tomorrow between Domain Therapeutics and a seasoned team from our university, led by Michel Bouvier, an international expert in basic molecular pharmacology research and an innovative mind,” said Genevieve Tanguay, vice-rector of Research, Creation and Innovation at the Universite de Montreal.

“McGill University has a proud history of innovation and product development in numerous fields, especially the life sciences”, said Dr. Rose Goldstein, McGill’s vice-principal (Research and International Relations). “We very much look forward to continuing this tradition through our partnership with Domain Therapeutics and the Universite de Montreal – a collaboration that has the potential to create new and better treatments for patients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Domain Therapeutics Appoints Professor Michel Bouvier
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs.
Tuesday, September 23, 2014
Domain Therapeutics Enters into Collaboration with XOMA
DTect-All™ platform will be used to screen for GPCR-directed allosteric modulator antibodies.
Wednesday, February 05, 2014
Domain Therapeutics Opens a North American Subsidiary at Montreal's NEOMED Institute
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All™ technology.
Tuesday, January 21, 2014
Domain Therapeutics and Ono Sign Collaboration Agreement
Collaboration agreement in the field of GPCR-based drug discovery.
Tuesday, October 23, 2012
Domain Therapeutics Closes EUR Two Million Funding Round
The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs.
Wednesday, July 18, 2012
Domain Therapeutics Wins EUR 933,000 Grant for Schizophrenia Project
GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies.
Wednesday, March 14, 2012
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease
Domain Therapeutics and Merck Serono Announce an Agreement to Develop Drugs for Parkinson’s Disease.
Monday, January 17, 2011
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!